The global viral vector manufacturing market size reached USD 1,469.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 8,512.2 Million by 2033, exhibiting a growth rate (CAGR) of 21.6% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1,469.6 Million |
Market Forecast in 2033
|
USD 8,512.2 Million |
Market Growth Rate 2025-2033 | 21.6% |
A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.
The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.
IMARC Group provides an analysis of the key trends in each sub-segment of the global viral vector manufacturing market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on type, disease, application and end user.
Breakup by Type:
Breakup by Disease:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Type, Disease, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global viral vector manufacturing market was valued at USD 1,469.6 Million in 2024.
We expect the global viral vector manufacturing market to exhibit a CAGR of 21.6% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic has led to the escalating demand for viral vector vaccines manufacturing for novel drug delivery to boost the immunity against the coronavirus infection.
The increasing number of cancer patients, along with the rising adoption of viral vector manufacturing to deliver HIV-inhibiting transgenes to Human Hematopoietic Stem Cells (HSCs), is primarily driving the global viral vector manufacturing market.
Based on the type, the global viral vector manufacturing market can be segmented into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. Currently, adeno-associated viral vectors hold the majority of the total market share.
Based on the disease, the global viral vector manufacturing market has been divided into cancer, genetic disorders, infectious diseases, and others. Among these, cancer currently exhibits a clear dominance in the market.
Based on the application, the global viral vector manufacturing market can be categorized into gene therapy and vaccinology. Currently, gene therapy accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global viral vector manufacturing market include Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and uniQure N.V.